Evgen Pharma plc (AIM: EVG), the clinical stage drug development company developing sulforaphane based medicines for the treatment of cancers and inflammation, announces that it has progressed discussions with the
Publication shows effectiveness of SFX-01 in patient derived glioblastoma cells University of Auckland data
Evgen Pharma plc (AIM: EVG), the clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases, announces preclinical data demonstrating that SFX-01 was effective in
Evgen Pharma plc (AIM: EVG), a clinical stage drug development company, announces further progress and an update on clinical trial plans for SFX-01 in glioblastoma (“GBM”).
Zak Mir highlights some of the most followed stocks on the small-cap London market and gives an overview in this video charting update.
Zak Mir highlights some of the most followed stocks on the small-cap London market and gives an overview in this video charting update.
Evgen Pharma plc (AIM: EVG), a clinical stage drug development company, is pleased to announce that all necessary regulatory approvals have now been received for the STAR trial (SFX-01 treatment
Zak Mir highlights some of the most followed stocks on the small-cap London market and gives an overview of the fundamentals in this video charting update.
Zak Mir highlights some of the most followed stocks on the small-cap London market and gives an overview of the fundamentals in this charting update. Here is our pick of the
Evgen Pharma plc (AIM: EVG), the clinical stage drug development company, is delighted to announce participation in the recently notified funding initiative for COVID-19 clinical trials by the medical research
The University of Dundee is leading the clinical trial of a new anti-inflammatory drug it is hoped may reduce instances of severe lung damage and death in Covid-19 patients.
